All News

Survivors of SJS/TEN face severe long-term physical and psychological effects, with major gaps in post-discharge care, support, and physician guidance.

The FDA approved selumetinib for adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas based on the KOMET trial.

Improving outcomes in chronic kidney disease relies on improving patient engagement.

Research shows a sharp rise in bisphenol-attributable metabolic disease since 2000, with annual costs exceeding $250 billion in North America.

Immune-boosting herbs were linked to lower autoantibody rates in patients before dermatomyositis onset, suggesting activation of alternative immune pathways.

The accelerated approval was based on a study that evaluated the efficacy in unresectable or metastatic nonsquamous NSCLC.

Previously treated patients with non–small cell lung cancer (NSCLC) saw durable results with andamertinib 240 mg.

A study links seborrheic dermatitis to multiple epithelial barrier diseases, supporting broader assessment for inflammation and barrier dysfunction.

Caregivers face communication challenges in coordinating patient care for older adults, highlighting the need for improved support and training.

Patients hospitalized for bronchiectasis exacerbations face higher mortality, longer stays, and greater costs than those with COPD or asthma.

An improvement in ophthalmological knowledge was seen compared with older large language models and ophthalmology trainees.

Rozanolixizumab shows promise in treating triple-seronegative myasthenia gravis, offering hope for patients with limited treatment options.

Long-term nitrogen dioxide exposure raises ovarian cancer risk, underscoring the need for stricter air quality measures.

Rachel A. Prusynski, DPT, PhD, discusses her study on how payment models affect home health care delivery and patient outcomes.

Semaglutide and tirzepatide led to the most weight loss across 22 trials, while liraglutide remains a cost-effective alternative as its patent expires.

Men who have sex with men (MSM) expressed interest in both monthly oral pills and injections every 6 months to prevent HIV.

Plozasiran gains FDA approval as the first treatment for familial chylomicronemia syndrome based on phase 3 PALISADE data.

The FDA approved epcoritamab with rituximab and lenalidomide for relapsed follicular lymphoma, offering a promising fixed-duration treatment option for patients after their first relapse.

Women under 50 who consume high levels of ultraprocessed foods have a higher risk of developing early-onset conventional colorectal adenomas.

Lower-income countries rarely gain timely access to FDA-approved drugs tested in their populations, highlighting major global and ethical disparities.

Targeted financing, clinician recruitment, and telehealth expansion are needed to improve rural primary care.

Guselkumab significantly inhibited structural joint damage and improved symptoms in active PsA through 48 weeks.

Infectious disease was hit hardest by funding cuts to NIH grant for clinical trials that did not align with the Trump administration's priorities.

Cuts to Medicaid could spell trouble for pediatric health, as millions of children rely on Medicaid to cover their hospital expenses.

Research challenges age cut-offs in AML treatment, advocating for flexible, individualized approaches based on continuous age assessment.

Patients 65 years and older had improved overall and cancer-specific survival after undergoing chemoradiotherapy for stage 2 NSCLC.

Topline results find that single-tablet regimen of bictegravir/lenacapavir had noninferior efficacy when patients switched from multitablet regimens in HIV.

A novel RTEL1 nonsense mutation was identified in a woman with multigenerational familial pulmonary fibrosis (PF), expanding the genetic spectrum of telomere-related lung disease and underscoring the importance of genetic testing in suspected inherited interstitial lung disease (ILD).